Very cool - congratulations! First ferroptosis conference in the 🇺🇸 Looking forward to it!

Thankful for recognition. Broers Tom en Wim Vanden Berghe strijden met eigen therapie tegen kinderkanker: “Ik leef met leukemie dankzij nieuwe medicijnen. Nu wil ik anderen helpen” hln.be/binnenland/bro… HLN.BE StichtingtegenKanker @komop_tgkanker

Here is our latest review by Francesca Maremonti in Cell Death & Differentiation. From a definition of #ferroptosis to clinical trial design for #ferrostatins. Great to work with Mauro Giacca and King's College London on advances tharapies. Ferroptosis (SPP 2306) nature.com/articles/s4141…

Check this out! Our last translational ferroptosis paper from excellent PhD student. Ferroptosis is a targetable detrimental factor in metabolic dysfunction-associated steatotic liver disease | Cell Death & Differentiation #ferroptosis #MASLD nature.com/articles/s4141…

Mark your calendars! The 1st FASEB #Ferroptosis conference, July 27-31 2025! We just posted our preliminary agenda! Spectacular line up and lots of space for short talks / late breaking speakers. Help us get the word out & come join us in 2025! FASEB events.faseb.org/event/11797f9e…

Cell Death-Related Ubiquitin Modifications in Inflammatory Syndromes: From Mice to Men mdpi.com/1682504 #mdpibiomedicines via Biomedicines MDPI

Big congrats to Geraldine Veeckmans for poster price award ⁦Cold Spring Harbor Asia⁩. Let’s translate ferroptosis inhibitors to clinic! ⁦FWO⁩ #ferroptosis

Another memorable CSHA ferroptosis meeting in Suzhou China. Thx to organisers and cell death community! Cold Spring Harbor Asia #ferroptosis

Interested in our work? Watch 'Knappe koppen' on national TV VRT1 Wednesday Dec 4 at 21h35. Geinteresseerd in ons werk? Kijk 'knappe koppen' op VRT1 woensdag 4 dec 21h35 vrt.be/nl/over-ons/ni…

While at Dana-Farber, Brian Bruker (now OHSU Knight Cancer Institute) started the personalized medicine revolution with the first targeted cancer drug, imatinib. The first of a series of BCR-ABL inhibitors that made Ph+ #CML a chronic disease. A transformative discovery.

The human proteomic revolution proceeds with high-throughput assessment, AI analytics, correlation with health and disease, drug interactions, biomarkers cell.com/cell/fulltext/…

Knappe koppen vrt.be/vrtmax/a-z/kna… Don't forget to watch tonight! Niet vergeten kijken deze avond.

🚀 Exciting opportunity! 🎓 The PhD program in Cancer and Immunology in Lausanne is accepting applications! If you're passionate about advancing research in cancer or immunology, we want to hear from you! 🌟 #PhD #CancerResearch #Immunology unil.ch/cancer-immunol… via Université de Lausanne

This is such an accurate representation of being a PhD student

Harnessing ferroptosis for precision oncology: challenges and prospects. New #openaccess Review from Fernández-Acosta Tom Vanden Berghe and co as part of our ‘#Ferroptosis’ Collection bmcbiol.biomedcentral.com/articles/10.11…

⚡️SAVE the DATE!!!! SAVE the DATE!!!!⚡️

Registration for ECDO2025 is now officially open. Secure your place at the legendary event in Berlin today ecdo.eu/ecdo2025/conte…

Mads Daugaard is striking again. High level of translational oncology presented @EWCD meeting in Fiuggi Italy.

Game changer in translational ferroptosis research. Check out this nature paper by Linkermann lab and his amazing team ! Oestrogen defends against kidney damage caused by iron-dependent cell death nature.com/articles/d4158…

📰 New paper alert! In case you missed it over the holidays: my News & Views on the latest work from the Linkermann Lab is out. rdcu.be/eBIqZ Congrats to the Linkermann team on this exciting study! 🎉 #ScienceTwitter #CellDeath #Research nature nature.com/articles/d4158…